Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease study 2013

Abstract

High-quality epidemiological studies evaluating the burden of cutaneous leishmaniasis worldwide are lacking. We compared the burden of cutaneous leishmaniasis in each country to the overall global burden and assessed the equality of cutaneous leishmaniasis burden across different countries and regions.

Methods

Data were extracted from scientific literature, hospital sources, country reports, and WHO sources on the prevalence of sequelae of both acute and chronic cutaneous leishmaniasis. Prevalence data were combined with a disability weight to yield years lived with disability. Disability-adjusted life years (DALYs) are a sum of the years lived with disability and years of life lost (or mortality, assumed to be zero). We compared DALYs due to cutaneous leishmaniasis for 152 countries using standard Z score analysis with Bonferroni correction (p<0.003) and generation of Lorenz curves with a Gini coefficient.

Findings

In 2013, the global mean age-standardized DALYs for cutaneous leishmaniasis was 0.58 per 100,000 people. Nine countries had significantly greater DALYs from cutaneous leishmaniasis than the mean: Afghanistan (87.0), Sudan (20.2), Syria (9.2), Yemen (6.2), Iraq (6.0), Burkina Faso (4.8), Bolivia (4.6), Haiti (4.1), and Peru (4.0). The Gini coefficient was 0.89. Andean Latin America, North Africa and Middle East, western sub-Saharan Africa, and South Asia had the highest DALYs from cutaneous leishmaniasis. Among males, Palestine had the highest incidence rates (616.2 cases per 100,000 people) followed by Afghanistan (566.4), Syria (357.1), and Nicaragua (354.8). Among females, Afghanistan had the highest incidence rates (623.9) followed by Syria (406.3), Palestine (222.1), and Nicaragua (180.8). Similar proportions of males and females had cutaneous leishmaniasis in most countries with a high incidence.

Interpretation

The burden from cutaneous leishmaniasis mainly falls on countries in Africa and the Middle East. Global and national data on the burden of cutaneous leishmaniasis disease are pivotal to promote field studies and initiate behavioral change.